Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ...

Researchers from the USC Norris Comprehensive Cancer Center and collaborators report that they have found evidence that targeting CD47, a protein that is part of the innate immune system, could be a ...

A new research paper was published in Volume 17, Issue 12 of Aging-US on December 1, 2025, titled “CD47 antisense oligonucleotide treatment improves glucose homeostasis and alleviates dyslipidemia in ...

Researchers from University of Kentucky report that antisense inhibition of CD47 improved glucose homeostasis, insulin ...

In a further sign of growing interest among large drugmakers in an emerging target for cancer immunotherapy drugs, a company in the space is getting an equity investment from one of the world’s ...

A characteristic of tumors includes the ability to avoid the immune system. In many cases tumors can progress without detection of immune cells. In the literature many scientists refer to undetectable ...

ALX Oncology (NASDAQ:ALXO) outlined progress across its two clinical-stage programs—CD47 blocker evorpacept and EGFR-targeted ...

Detailed price information for Alx Oncology Holdings Inc (ALXO-Q) from The Globe and Mail including charting and trades.

One of the most disturbing things about the ongoing coronavirus disease 2019 (COVID-19) pandemic is the unpredictability of the eventual outcome of the infection. Caused by the severe acute ...